Following a slight dip in the last session, Eli Lilly (LLY) shares gained ~5% on Monday as Leerink Partners upgraded the ...
Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.
Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...
TipRanks on MSN
uniQure price target lowered to $60 from $68 at Leerink
Leerink lowered the firm’s price target on uniQure (QURE) to $60 from $68 and keeps an Outperform rating on the shares following quarterly results ...
In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...
The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while deal value has already eclipsed last year’s total. | The number of biopharma ...
Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...
Immunic, Inc. (NASDAQ:IMUX – Free Report) – Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings estimates for Immunic in a research note issued on Tuesday, April 1st. Leerink ...
The gross proceeds to Evommune from the initial public offering before deducting underwriting discounts and commissions and offering expenses were $172.5 million. The shares began trading on the New ...
) or the potential repurchase of L'Oreal's 9% stake. Leerink Swann commented that they continue to see long-term opportunity for products including alirocumab and dupilumab, but "we are skeptical that ...
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) got upgraded to Outperform from Market Perform by Leerink Partners. The ...
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback